GenomeDx

GenomeDx

  • COLLABORATION.
  • INNOVATION.
  • SOLUTIONS.
SCROLL
ACCELERATING THE DEVELOPMENT OF NEW GENOMIC SOLUTIONS FOR CANCER.

We believe our unique data sharing platform creates a network effect among its users to rapidly develop and validate new genomic solutions to answer critical clinical questions. The Decipher GRID program aims to improve cancer patient care by harnessing the power of collaboration.

GRID

GENOMICS RESOURCE
INFORMATION DATABASE

GENOMICS RESOURCE INFORMATION DATABASE (GRID)

The Decipher GRID research program features what we believe is the fastest growing tumor RNA expression database for urologic cancers with over 27,000 genomic profiles. Each profile consists of over 1.4 million markers covering 46,000 coding and non-coding genes and contains the patient demographics, clinical information and pathology features. Through this innovative data sharing and collaborative research platform, the GRID program has already contributed to over 45 scientific publications and several novel genomic solutions used in the clinic today. The GRID program serves as a rich resource to the urology and oncology communities that aims to transform the treatment and management of cancer.

DECIPHER GENOMIC CANCER CLASSIFIERS

The Decipher cancer classifiers are CLIA-certified, laboratory developed tests that utilize genomic expression information to provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making. The Decipher assay captures a high resolution view of the transcriptome with over 1.4 million data points per tumor, enabling new GRID discoveries. Once validated these genomic solutions then become available for clinical use.

LEARN MORE ABOUT DECIPHER GENOMIC CANCER CLASSIFIERS

REIMAGINING THE USE OF GENOMIC INFORMATION

GenomeDx uses the power of collaborative genomics to transform the management and treatment of cancer patients. By analyzing large amounts of complex data, GenomeDx is developing tools that enhance the way patient care is managed. Our goal is to increase the efficiency of practice management, optimizing decision-making related to patient care, and improving outcomes for our patients.

Through the capture, analysis and exchange of genomic information, GenomeDx is working to change the way cancer is understood.

LEARN MORE ABOUT GENOMEDX

FOR YOUR PATIENTS

By ordering the Decipher cancer classifiers, a physician can also access the GRID Tumor RNA Expression Profile to further explore the patient's tumor biology. GRID profiles include over 70 genes and signatures that reveal the tumor's molecular subtypes and active biological pathways as well as predicting tumor stage, recurrence risk and response to therapy.

This RESEARCH USE ONLY data has been developed by our extensive network of research collaborators or curated from literature.  GRID genomic markers and signatures are being tested in ongoing clinical trials and once validated will be available for routine clinical use.

SAMPLE GRID TUMOR PROFILE

GRID GENOMIC MARKERS

TUMOR RNA
EXPRESSION PROFILE

FOR YOUR CLINICAL RESEARCH

The primary objective of the Decipher GRID program is to foster data sharing and research collaborations in order to better understand cancer tumor biology with genomic data. Together, we can accelerate discovery and translation of new genomic solutions into the clinic.

In addition to the GRID Tumor RNA Expression Profile, researchers can receive a Dynamic Database that aggregates the expression levels, percentile rank and outlier calls for hundreds of genes and signatures for all your Decipher patients.

If you’d like to discuss the opportunity to partner with us for a research study, please contact us to obtain access to even more GRID data.

DECIPHER GRID CLINICAL TRIAL

PUBLICATIONS

DATA-SHARING AND
RESEARCH PLATFORM

PARTICIPATE IN ADVANCING CANCER RESEARCH

Every tumor is unique. The Decipher assay measures over 1.4 million expression markers from your tumor tissue. In addition to your Decipher cancer classifier results, you can receive your GRID tumor profile, which can be used to better characterize your tumor and may help your physician to better personalize your cancer care. In addition, by participating in the GRID program you are contributing to research that advances the understanding of cancer that we believe will accelerate new ways to combat cancer.

Talk to your doctor today about the Decipher Cancer Classifiers and GRID program

EXPLORE YOUR
TUMOR GENOME

OUR
NETWORK

With over 300 GRID physicians, our network continues to grow feeding more data into the GRID to power new discoveries in cancer.  To find a physician near you, please contact us.

GRID PHYSICIANS

Decipher GRID is a hub in cancer research and has been used in more than 45 clinical studies published in collaboration with over 55 leading cancer centers.

GRID RESEARCHERS

Our GRID patient population is growing by approximately 1,300 tumor profiles a month.

27,000+
Tumor Profiles

GRID PATIENTS

ACCESS

HOW TO ACCESS GRID RESEARCH PROFILES

Order the Decipher Test and receive access to your patient's GRID Tumor RNA Expression Profile.

LEARN MORE ABOUT THE DECIPHER TEST

Become a GRID physician and you can receive the Dynamic Database* for all your patients.
* Available once you order 10 Decipher Tests.

If you are already part of our GRID physician network and want to access your GRID results, please click here.

GRID PROFILES FOR
YOUR PATIENTS

HOW TO ACCESS GRID RESEARCH DATA

If you are currently ordering the Decipher Test and would like to become a GRID researcher, please contact your sales representative to discuss how to join our program.

If you are interested in joining the GRID research program and are NOT currently ordering Decipher tests, please complete the following contact form and provide additional information about your research interests. A GenomeDx representative will reach out to discuss the next steps.

CONTACT US ABOUT BECOMING A GRID RESEARCHER

GRID DATA FOR YOUR
RESEARCH STUDY

HOW TO ACCESS YOUR TUMOR PROFILE

The GRID program is available to patients who have had the Decipher test performed. If you have not had this test ordered, please discuss with your physician or contact us to be connected with a GRID physician.

If you have had the Decipher test performed, please contact your physician to request your GRID profile or contact us.

CONTACT US

YOUR PERSONALIZED
TUMOR PROFILE

SCIENCE

DECIPHER GRID TECHNOLOGY + PUBLICATIONS

TRANSCRIPTIONAL PROFILING OF TUMORS

The Decipher assay is performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples using microarray technology to capture the expression levels for over 46,000 coding and non-coding genes across the genome. From over 1.4 million expression markers measured, a subset of markers are used in a proprietary algorithm to compute the Decipher cancer classifier score. After de-identification, the entire expression profile is processed through our GRID analysis pipeline. The raw data and normalized expression levels are stored within the GRID database and made available to researchers for further analyses.



GRID TECHNOLOGY

RECENT PUBLICATIONS

SEPTEMBER 2016

Benzon B., et al. Correlation of B7-H3 with Androgen Receptor, Immune Pathways and Poor Outcome in Prostate Cancer:  An Expression Based Analysis. PCAN. 2016. In press.

AUGUST 2016

Den R.B., et. al. Decipher correlation patterns post-prostatectomy: Initial experience from 2,342 prospective patients. Prostate Cancer and Prostatic Disease. 2016.  doi: 10.1038/pcan.2016.38. 

Klein E.A., et al.  Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential.  Journal of Urology. 2016. pii: S0022-5347(16)31146-6.  

JULY 2016

White N.M., et al. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. Eur Urol. 2016 Jul 22. pii: S0302-2838(16)30417-1. doi:10.1016/j.eururo.2016.07.012.

Morlacco A., Karnes R.J. Early salvage radiation therapy post-prostatectomy: key considerations. Future Oncol. 2016 Jul 8.

Stoyanova R, et al. Association of Multiparametric MRI Quantitative Imaging Features with Prostate Cancer Gene Expression in MRI-targeted Prostate Biopsies. Oncotarget. 2016.

VIEW ALL PUBLICATIONS

GRID PUBLICATIONS

JOIN
THE GRID
NETWORK